Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
44,900
+1,700 (3.94%)
At close: Dec 5, 2025
95.64%
Market Cap 648.02B
Revenue (ttm) n/a
Net Income (ttm) -39.26B
Shares Out 14.43M
EPS (ttm) -2,754.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 444,705
Average Volume 98,319
Open 46,000
Previous Close 43,200
Day's Range 43,200 - 48,550
52-Week Range 19,390 - 48,550
Beta 1.49
RSI 64.86
Earnings Date Nov 13, 2025

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.